Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Siegfried Transfers A Plant To Celgene
by Rick Mullin
July 20, 2015
| A version of this story appeared in
Volume 93, Issue 29
Swiss fine chemicals maker Siegfried has sold a production building at its facility in Zofingen, Switzerland, to the biotech firm Celgene. The agreement builds on a contract signed 10 years ago under which Celgene has exclusive rights to capacity in Zofingen for production of the active ingredient in its multiple myeloma drug Revlimid. Separately, German and French authorities have green-lighted Siegfried’s acquisition, announced earlier this year, of three European custom synthesis sites from BASF.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X